Ohio State Navbar

Directory

Spero Cataland, MD


Staff photo

320 W 10th Ave
Columbus, OH 43210

Phone: (614) 293-2887

Email: cataland.2@osu.edu

 

Current OSU Appointments

Professor-Clinical, Hematology

Physician, FGP-Hematology

Associate Professor-Clinical, Pathology

 

Academic Advising

Representative to the Department of Medicine for Faculty Mentorship Group.

Biographical

Research

With the assistance of my collaborator in the Department of Pathology, Dr. Haifeng Wu, we have established and expanded The Ohio State University Thrombotic Thrombocytopenic Purpura (TTP) Research Program dramatically over the past year. Since initiating this research program now 10 years ago, we have enrolled over 80 patients and banked over 3,000 plasma samples for present and future study, not an insignificant accomplishment for such rare disease. Our work has resulted in the publication of over 40 peer-reviewed articles in peer-reviewed journals as well as several abstracts that have been presented in both oral and poster forms at international meetings in the field. We have also patented a novel methodology to measure a laboratory biomarker in TTP and have established Dr. Haifeng Wu’s research lab as a CAP certified, national reference lab for the clinical evaluation of ADAMTS13 biomarkers.

We have completed 2 prospective therapeutic trials evaluating the use of adjuvant immune-suppressive therapy as an adjunct to plasma exchange. These studies have led to a multi-center, prospective randomized trial of corticosteroids or cyclosporine as an adjunct to plasma exchange which we as the lead institution and have opened and have begun accruing patients. This study is presently ongoing and being supported by an R01 from the FDA for which I am the co-principal investigator

Based on the accomplishments of our research program, we previously entered into an agreement with the Archemix Corporation to conduct an observational and retrospective study in TTP, the goal of which is to eventually proceed with a multinational, randomized study of a novel therapy for TTP. I was appointed to the steering committee of this international study and that was closed prematurely, but the initial results of the study were published with myself as the lead author.

Based upon my involvement and leadership in the previously mentioned study, I was asked to be the North American Study Coordinator and consultant to Ablynx for a multicenter, international therapeutic TTP study similarly using an A1 domain targeting therapy. This clinical trial studying a truly novel TTP therapy is presently accruing patients internationally with Ohio State being the lead North American site. I also serve as a consultant for the ongoing management of this study and eventually the analysis and publication of the data when the study is complete.

An additional focus of our work in the Ohio State TTP Research program has centered around study novel laboratory biomarker data to objectively and accurately differentiate TTP from other forms of thrombotic microangiopathies that require a different and unique form of therapy. We have developed a panel of ADAMTS13 and complement activation biomarkers that are being studied regarding their ability to differentiate these disorders as well as predict clinical outcome. We recently received a $200,000 research grant from Alexion to further expand these research efforts in patients with aHUS. Additionally, we just received a $200,000 research grant from the Answering TTP Foundation to expand our efforts to study the role of complement activation in patients acutely presenting with the diagnosis of TTP and throughout long term follow-up.

We expect both the number of publications and the significance of these publications and the influence of our work to continue to increase in the coming years. Our research program is unique in its laboratory and clinical expertise that allows us to conduct basic science and mechanistic studies, but also to enable us to lead international TTP and aHUS studies given our expertise and expansive cohort of patients followed. Increases in research funding more recently will provide the resources required to continue to expand the impact of the Ohio State TTP Research Program. Additional grant proposals supporting our studies of complement activation in patients with thrombotic microangiopathies (TTP and aHUS) have been submitted and favorably scored which will help support the continued growth of our program.

Education
Since joining the faculty in of Ohio State University I have been active in the teaching of medical students, residents, and fellows. I was involved in curriculum development having designed and helped to implement the Hematologic Pathophysiology Independent Study module for the second year Independent Study Program. In addition, I have been a regular lecturer in the college of medicine for both students in the second year of medical school as well as third year students as they go through their internal medicine rotations. I am also very active in the mentoring and clinical teaching of medical students, residents and fellows on in the patient benign hematology consult service as well as in my outpatient clinic. I received the Bertha Bourncle Teaching Award in 2007 which is given recognize the teacher of the year in the Division of Hematology. The reviews and evaluations received from students, fellows, and from peers/audience members from the numerous lectures, invited presentations, and CME presentations I believe support the effectiveness of my teaching skills.

Service
Despite my active research responsibilities, I have maintained an active clinical practice where I see outpatients with benign hematologic diseases 2 days per week. In addition I continue to attend on the inpatient hematology consult service 4 months each year. Administratively, I am an active member of several important committees at the university and the hospital as detailed in my dossier below. I also serve as the director of mentorship for the Division of Hematology and am the mentorship representative to the Department of Medicine from the Division of Hematology. I also have been a member of the Biomedical Sciences Institutional Review Board for the past year and have recently joined the Promotion and Tenure Committee for the Department of Internal Medicine.

Licenses

2000 - present Medical License - 35-06-9289-C: State Medical Board of Ohio
2010 - present Board Certification: American Board of Hematology
1997 - 2007 Board Certification: American Board of Internal Medicine
2000 - 2010 Board Certification: American Board of Internal Medicine
2000 - 2010 Board Certification: American Board of Internal Medicine
 

Chapters in Books

Myelodysplasia

[Treatment of adult acute lymphoblastic leukemia]

Hematalogic Issue

Excessive Bleeding with Normal Prothrombin Time, Partial Thromboplastin Time and Platelet Count.

 

Clinical Services

12/01/2006 Hematology Consultation Service (James Cancer Hospital, Internal Medicine, Hematology/Oncology)
10/01/2009 Associate Professor of Clinical Medicine (2nd floor James Cancer Hospital, Hematology)
09/01/2012 Associate Professor of Clinical Medicine (James Care East)
07/01/2014 Hematology Out-Patient Clinic (2nd Floor James Cancer Hospital Clinic)
07/01/2014 In-Patient Hematology Consulatation Service (James Cancer Hospital)
07/01/2014 Hematology Out-Patient Clinic (JamesCare East)
01/01/2001 - 09/01/2009 Assistant Professor of Clinical Medicine (2nd floor of the James Cancer Hospital, Hematology/Oncology)

Conferences

Improved clinical outcome and ADAMTS13 activity following cyclosporine therapy in patients with TTP.

Cyclosporine and plasma exchange is superior to corticosteroids and plasma exchange as initial therapy of TTP

Cyclosporine alone for the treatment of early recurrences of TTP

Low ADAMTS13 activity in clinical remission predicts the risk of TTP relapses

Cyclosporine is effective prophylactic therapy in preventing recurrences of TTP

ADAMTS13 antigen levels and the risk of relapse during long-term clinical follow up of patients with idiopathic thrombotic thrombocytopenic purpura.

Clinical utility of ADAMTS13 biomarkers in the evaluation of TTP

A Randomized, Double-Blind, Placebo-Controlled, Clinical Outcome Study of ARC1779 In Patients with Thrombotic Thrombocytopenic Purpura (TTP)

Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia

 

Degrees

1990 B.S., The Ohio State University

1994 M.D., The Ohio State University

 

Editorial Activities

2004 - present British Journal of Haematology
2004 - present Blood
2005 - present Thrombosis and Hemostasis
2005 - present American Journal of Hematology
2008 - present Nature Clinical Practice Cardiovascular
2008 - present Nature Cardiovascular Medicine
 

Honors

1990 - 1991 Summa Cum Laude.
1990 - 1991 College of Business Pacesetter Award.
1992 - 1993 Cancer Research Assistant Program Grant.
1999 - 1998 Amgen Fellow.
1999 - 2000 Kaminer Award.
2007 Bertha Bouroncle Distinguished Faculty Teaching Award. Division of Hematolgoy/Oncology.
 

Journal Articles

.

"Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology.." Journal of the National Comprehensive Cancer Network : JNCCN. Vol. 6, no. 8. (September 2008.): -.

"Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura." HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. Vol. 95, no. 9. (September 2010.): -.

"Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials." CANCER CHEMOTHERAPY AND PHARMACOLOGY. Vol. 65, no. 2. (January 2010.): -.

 

Reference Works

January 1998 Cataland SR, Clementi B, Daugherty, CK, Larson RA.."Preliminary experience with a novel of post-remission chemotherapy regimen for adults with acute lymphoblastic leukemia." . : 255a
January 1998 Cataland SR, Kuzel T, Vogelzang NJ, Stadler WM.."A Phase II Trial of Radiation (RT) and Outpatient Subcutaneous IL-2 Plus GM-CSF in Patients with Metastatic Renal Cell Cancer." . : 1262
January 1999 Cataland SR, Weseman E, Daugherty CK, Larson RA."Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia." . : 296a
January 1999 Cataland SR, Thirman MJ."Molecular and clinical analysis of MLL-ELL translocations inpatients with acute leukemia." . : 498a
January 2004 Cataland SR, George JN, Kraut EH, Bourgeois TT, Ferketich AK, Kennedy MS, Caligiuri MA, Wu HM.."Improved Clinical Outcome and ADAMTS13 Activity Following Cyclosporine Therapy in Patients with TTP" . : 243a
November 2004 William Blum, Kristie A. Blum, Cheryl Kefauver, Mollie Moran, Kenneth Chan, John C. Byrd, Spero Cataland, Michael R. Grever, Guido Marcucci."Decitabine-Induced Differentiation Syndrome in a Patient with Acute Myeloid Leukemia: A Case Report." .
November 2005 Eric H. Kraut, Spero R. Cataland, Leslie Witkoff, Sylvia Jordan, William T. Gunning."Evaluation of Qualitative Platelet Disorders in Patients with Hemophilia" .
November 2005 Spero R. Cataland, Ming Jin, Amy K. Ferketich, Eric H. Kraut, James N. George, Haifeng M. Wu.."Cyclosporine and Plasma Exchange is Superior to Corticosteroids and Plasma Exchange as Initial Therapy of TTP" .
November 2005 Kurt P. Leuenberger, Spero Cataland, Ming Jin, Carol Orr, Guido Marcucci, Eric H. Kraut, Haifeng Wu."Distinguishing Antiphospholipid Antibodies from an Acquired Factor Inhibitor: A Novel Laboratory Approach." .
November 2005 Guido Marcucci, W. Stock, J.A. Zwiebel, S.R. Cataland, G. Dai, M. Moran, D. Lucas, S. Liu, M.I. Klisovic, C. Kefauver, M. Green, K. K. Chan, S. R. Frankel, M.R. Grever, J.C. Byrd."Clinical Activity of Genasense (GNS, Oblimersen Sodium), a Pro-Apoptotic to Bcl-2 Oligonucleotide, in combination with Daunorubicin and Cytarbine: A Phase I Study in Previously Untreated Elderly Acute Myeloid Leukemia (AML)." .
November 2005 Spero R. Cataland, Min Jin, Amy K. Ferketich, X. Long Zheng, James N. George, Haifeng M. Wu.."Cyclosporine Alone for the Treatment of Early Recurrences of TTP." .
November 2005 Subha V. Raman, Orlando P. Simonetti, Spero R. Cataland, William J. Hicks, Eric H. Kraut."Myocardial Ischemia without Coronary Artery Obstruction in Patients with Sickle Cell Disease." .
November 2005 Haifeng Wu, Spero Cataland, Michael Bissell, Ming Jin.."A Rapid Test for the Diagnosis of Thrombotic Thrombocytopenic Purpura Using SELDI-TOF-Mass Spectrometry." .
November 2005 Wendy Stock, Daohal Yu, Ben Sanford, Gerard Lozanski, Spero Cataland, Ravi Vij, John Byrd, Bayard Powell, Meir Wetzler, Maher Albitar, Dorie Sher, Colin Edwards, Eva Hoke, Clara D. Bloomfield, Richard A. Larson."Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102)" .
November 2006 Spero R. Cataland, Eric H. Kraut, Don Benson, Amy K. Ferketich, April Horne, Ming Jin, James N. George, Haifeng M. Wu.."Improved Clinical Outcome and ADAMTS13 Activity after Concurrent Cyclosporine and Plasma Exchange in TTP" .
January 2007 Cataland SR, Jin, M, Lin S, Kennedy MS, Kraut EH, George JN, and Wu HM.."ADAMTS13 Antigen Levels and the Risk of Relapse During Long-Term Follow-Up of Patients with Idiopathic Thrombotic Thrombocytopenic Purpura." . : 3204a
April 2008 Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Burgt JV, Van laar E, Cullen M, Macleod AR, Besterman JM, Reid GK, Byrd JC, Marcucci G.."A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia." . : 2444-9
May 2008 Jin M, Casper TC, Cataland SR, Kennedy MS, Lin S, Li YJ, Wu HM.."Relationship between ADAMTS 13 activity in clinical remission and the risk of TTP relapse." . : 8
March 2011 Eric H. Kraut."." .
October 2011 Dr. Eric Kraut."." .

Inventions and Patents

A diagnosis test for Thrombotic Thrombocytopenia Purpura using SEDLI-TOF Spectrometer.

 

Presentations

Advances in Thrombotic Thrombcytopenic Purpura

Hematologic Disorders of Pregnancy

Doctor, Why Am I Bruising So Easily?

Immune Based Therapy of TTP

Prospective Studies with Long-Term Follow-Up of Corticosteroids and Cyclosporine Given Individually as Adjuncts to Plasma Exchange in the Initial Treatment of TTP

Evaluating Coagulopathies

Differentiating the Thrombotic Microaniopathies: The Role of ADAMTS13 Activity Testing in TTP

Venous Thromboembolid Disease and Hypercoagulable Disorders

Randomized Study of Cyclosporine or Corticostero8ids and Plasma Exhcnage as the Initial Therapy of Thrombotic Thrombocytopenic Purpura

Nplate for Chronic Immune Thrombocytopenic Purpura

ADAMTS13 Activity, Race, and Age as Predictors of Exacerbation in Patients with Idiopathic Thrombotic Thrombocytopenic Purpura (TTP)

ITP

Objective Documentation of Neurologic Injury in Patients with Idiopathic Thrombotic Thrombocytopenia Pupura (TTP)

Hypercoaguable State

(ITP) Idiopathic Thrombotic Purpura

Genetic Testing in Venous Thromboembolic Disease: Does it Really Matter Clinically?

aHUS and (TTP) Thrombotic Thrombocytopenic Purpura

Advances in Diagnosis and Treatment of aHUS

Diagnosis and Management of Microangiopathic Hemolytic Anemias.

Changing Perspectives on TTP and Atypical HUS

Challenges in Differentiating the Thrombotic Microangiopathies. TTP and aHUS Symposium.

Evolving Understanding of Atypical Hemolytic Uremic Syndrome.

Treatment options for TTP and atypical HUS in the 21st century.

Complement Medicated Thrombotic Microangiopathies

Advances in the Management of Complement-Mediated Thrombotic Microangiopathies.

HEPARIN-INDUCED THROMBOCYTOPENIA

 

Professional Activities

2006 - present Panel Expert for Net Wellness, Consumer Health Information. Net Wellness, Consumer Health Information. Columbus, OH.
2008 - present National Study Coordinator for Archemix 006 Clinical Trial. Archemix.
2008 - present Invited Member of International Steering Committee. Archemix.
2009 - present Thrombotic Thromboctytopenic Purpura (TTP) Patient Support Group Meeting.
2010 - present Expert to the Answering Thrombotic Thrombocytopeni Purpura (TTP) Foundation.
2010 - present Atypical Hemolytic Uremic Syndrome International Advisory Board Meeting. Alexion Pharmaceuticals. Orlando, FL.